Medicare Part D drugs starting with S
130 drugs start with S; 54 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Stelara in 2024: $3.4 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with S?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Sabril (vigabatrin) | under 0.1% | Tier 1 | $15 million |
| Sacubitril / valsartan | 99.6% | Tier 3 | no 2024 match |
| Safyral (drospirenone / ethinyl estradiol / levomefolate calcium) | 0.3% | Tier 4 | $6 thousand |
| Sajazir (icatibant) | 68.9% | Tier 5 | $2 million |
| Salagen (pilocarpine hydrochloride) | under 0.1% | Tier 1 | $31 thousand |
| Salmon calcitonin | 100% | Tier 3 | no 2024 match |
| Samsca (tolvaptan) | under 0.1% | Tier 1 | $9 million |
| Sancuso (granisetron) | 20.7% | Tier 5 | $7 million |
| Sandimmune (cyclosporine) | 2.1% | Tier 4 | $463 thousand |
| Sandostatin (octreotide) | 0.1% | Tier 4 | $197 thousand |
| Santyl (collagenase) | 98.7% | Tier 4 | $191 million |
| Saphris (asenapine) | 0.6% | Tier 1 | $7 million |
| Sapropterin dihydrochloride | 100% | Tier 5 | $16 million |
| Savella (milnacipran hydrochloride) | 32.9% | Tier 3 | $59 million |
| Saxagliptin | 10.7% | Tier 3 | $14 million |
| Scemblix (asciminib) | 100% | Tier 5 | $197 million |
| Scopolamine | 100% | Tier 4 | $31 million |
| Secuado (asenapine) | 100% | Tier 5 | $6 million |
| Segluromet (ertugliflozin / metformin hydrochloride) | 0.5% | Tier 4 | $1 million |
| Selarsdi (ustekinumab-aekn) | 19.4% | Tier 3 | no 2024 match |
| Selegiline hydrochloride | 100% | Tier 3 | $5 million |
| Selenium sulfide | 99.7% | Tier 2 | $757 thousand |
| Selzentry (maraviroc) | 100% | Tier 5 | $4 million |
| Semglee (insulin glargine-yfgn) | 0.1% | Tier 3 | $65 million |
| Sephience (sepiapterin) | 2.6% | Tier 5 | no 2024 match |
| Serevent (salmeterol) | 78.3% | Tier 3 | $37 million |
| Seroquel (quetiapine) | under 0.1% | Tier 1 | $16 million |
| Serostim (somatropin) | 4.5% | Tier 5 | $110 million |
| Sertraline | 100% | Tier 1 | $148 million |
| Setlakin (ethinyl estradiol / levonorgestrel) | 93.1% | Tier 2 | $79 thousand |
| Sevelamer carbonate | 33.1% | Tier 4 | $142 million |
| Sevelamer hydrochloride | 4.3% | Tier 2 | $24 million |
| Seysara (sarecycline) | 2.3% | Tier 5 | $786 thousand |
| Sharobel (norethindrone) | 95.6% | Tier 2 | $22 thousand |
| Shingrix (shingles vaccine) | 100% | Tier 1 | $776 million |
| Signifor (pasireotide) | 100% | Tier 5 | $2 million |
| Siklos (hydroxyurea) | 28.1% | Tier 4 | $961 thousand |
| Sildenafil | 100% | Tier 3 | $39 million |
| Silenor (doxepin) | under 0.1% | Tier 1 | $504 thousand |
| Siliq (brodalumab) | 3.6% | Tier 5 | $9 million |
Show the other 90 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Silodosin | 63% | Tier 3 | $25 million |
| Silvadene (silver sulfadiazine) | 0.1% | Tier 1 | $29 thousand |
| Silver sulfadiazine | 100% | Tier 2 | $5 million |
| Simbrinza (brimonidine tartrate / brinzolamide) | 80.6% | Tier 3 | $79 million |
| Simlandi (adalimumab-ryvk) | 20.8% | Tier 5 | $529 thousand |
| Simponi (golimumab) | 0.8% | Tier 5 | $185 million |
| Simvastatin | 100% | Tier 1 | $126 million |
| Sinemet (carbidopa / levodopa) | under 0.1% | Tier 1 | $307 thousand |
| Singulair (montelukast) | under 0.1% | Tier 1 | $6 million |
| Sirolimus | 100% | Tier 4 | $17 million |
| Sirturo (bedaquiline) | 100% | Tier 5 | $3 million |
| Sitagliptin | 2.9% | Tier 3 | $3 million |
| Sivextro (tedizolid phosphate) | 30.7% | Tier 5 | $17 million |
| Skyclarys (omaveloxolone) | 23.6% | Tier 5 | $101 million |
| Skyla (levonorgestrel) | 15.6% | Tier 4 | $12 thousand |
| Skyrizi (risankizumab-rzaa) | 98.4% | Tier 5 | $2.1 billion |
| Skytrofa (lonapegsomatropin-tcgd) | 0.3% | Tier 5 | $159 thousand |
| Smoking cessation | 100% | Tier 2 | no 2024 match |
| Soaanz (torsemide) | 1.2% | Tier 1 | $5 million |
| Sodium chloride | 100% | Tier 2 | $48 thousand |
| Sodium oxybate | 81.2% | Tier 5 | $79 million |
| Sodium phenylbutyrate | 97.4% | Tier 5 | $3 million |
| Sodium polystyrene sulfonate | 100% | Tier 3 | $3 million |
| Sofosbuvir / velpatasvir | 39.9% | Tier 5 | $109 million |
| Sogroya (somapacitan-beco) | 0.3% | Tier 5 | $1 million |
| Sohonos (palovarotene) | 2.2% | Tier 5 | $3 million |
| Solifenacin succinate | 97.7% | Tier 2 | $67 million |
| Soliqua (insulin glargine / lixisenatide) | 91.8% | Tier 3 | $300 million |
| Solosec (secnidazole) | 0.4% | Tier 4 | $56 thousand |
| Soltamox (tamoxifen) | 100% | Tier 5 | $525 thousand |
| Somavert (pegvisomant) | 100% | Tier 5 | $37 million |
| Soolantra (ivermectin) | under 0.1% | Tier 1 | $1 million |
| Sorafenib | 100% | Tier 5 | $21 million |
| Sotalol hydrochloride | 100% | Tier 2 | $24 million |
| Sotyktu (deucravacitinib) | 41.3% | Tier 5 | $62 million |
| Sotylize (sotalol hydrochloride) | 4.8% | Tier 4 | $52 thousand |
| Sovaldi (sofosbuvir) | 3.8% | Tier 5 | $2 million |
| Spevigo (spesolimab-sbzo) | 2.5% | Tier 5 | $5 million |
| Spinosad | 1.1% | Tier 4 | $382 thousand |
| Spiriva (tiotropium) | 100% | Tier 3 | $1.4 billion |
| Spironolactone | 100% | Tier 1 | $81 million |
| Sprintec (ethinyl estradiol / norgestimate) | 97.5% | Tier 2 | $347 thousand |
| Spritam (levetiracetam) | 96.3% | Tier 4 | $1 million |
| Sprycel (dasatinib) | 0.6% | Tier 5 | $518 million |
| SPS (sodium polystyrene sulfonate) | 97.7% | Tier 3 | $14 million |
| SSD (silver sulfadiazine) | 99.1% | Tier 2 | $5 million |
| Starjemza (ustekinumab-hmny) | 18.7% | Tier 4 | no 2024 match |
| Steglatro (ertugliflozin) | 0.5% | Tier 4 | $17 million |
| Steglujan (ertugliflozin / sitagliptin) | 0.2% | Tier 4 | $978 thousand |
| Stelara (ustekinumab) | 72.7% | Tier 5 | $3.4 billion |
| Steqeyma (ustekinumab-stba) | 33.9% | Tier 4 | no 2024 match |
| Stimufend (pegfilgrastim-fpgk) | 1.2% | Tier 5 | no 2024 match |
| Stiolto (olodaterol / tiotropium) | 62.2% | Tier 3 | $449 million |
| Stivarga (regorafenib) | 100% | Tier 5 | $96 million |
| Stoboclo (denosumab-bmwo) | 33.9% | Tier 4 | no 2024 match |
| Streptomycin | 100% | Tier 5 | $2 million |
| Stribild | 100% | Tier 5 | $23 million |
| Striverdi (olodaterol) | 31.7% | Tier 3 | $5 million |
| Stromectol (ivermectin) | under 0.1% | Tier 1 | $995 |
| Suboxone (buprenorphine / naloxone) | 16.7% | Tier 4 | $71 million |
| Subvenite (lamotrigine) | 99.4% | Tier 1 | $88 thousand |
| Sucraid (sacrosidase) | 30.4% | Tier 5 | $108 million |
| Sucralfate | 100% | Tier 2 | $129 million |
| Suflave (magnesium sulfate and 4 more ingredients) | 38.7% | Tier 4 | $4 million |
| Sugar-free cholestyramine resin | 100% | Tier 2 | no 2024 match |
| Sular (nisoldipine) | under 0.1% | Tier 1 | $319 thousand |
| Sulfacetamide sodium | 100% | Tier 2 | $2 million |
| Sulfadiazine | 100% | Tier 5 | $765 thousand |
| Sulfamethoxazole / trimethoprim | 100% | Tier 1 | $23 million |
| Sulfamylon (mafenide) | 34.7% | Tier 4 | $51 thousand |
| Sulfasalazine | 100% | Tier 2 | $18 million |
| Sulindac | 100% | Tier 2 | $3 million |
| Sumatriptan | 100% | Tier 2 | $47 million |
| Sunitinib | 100% | Tier 5 | $44 million |
| Sunlenca (lenacapavir) | 100% | Tier 5 | $18 million |
| Sunosi (solriamfetol) | 4.4% | Tier 3 | $21 million |
| Suprep Bowel Prep (magnesium sulfate / potassium sulfate / sodium sulfate) | 14.6% | Tier 4 | no 2024 match |
| Sutab (magnesium sulfate / potassium chloride / sodium sulfate) | 61.2% | Tier 3 | $25 million |
| Sutent (sunitinib) | under 0.1% | Tier 1 | $5 million |
| Syeda (drospirenone / ethinyl estradiol) | 88% | Tier 2 | $114 thousand |
| Symbicort (budesonide / formoterol fumarate) | 35.2% | Tier 3 | $598 million |
| Symdeko (ivacaftor / tezacaftor) | 27.7% | Tier 5 | $16 million |
| Symfi (efavirenz / lamivudine / tenofovir disoproxil fumarate) | 2.3% | Tier 5 | $645 thousand |
| Sympazan (clobazam) | 100% | Tier 4 | $3 million |
| Symproic (naldemedine) | 3.3% | Tier 3 | $10 million |
| Symtuza | 100% | Tier 5 | $448 million |
| Synarel (nafarelin) | 51.5% | Tier 5 | $230 thousand |
| Synjardy (empagliflozin / metformin hydrochloride) | 65.2% | Tier 3 | $501 million |
| Synthroid (levothyroxine sodium) | 92.6% | Tier 3 | $348 million |
| Syprine (trientine hydrochloride) | under 0.1% | Tier 1 | $1 million |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans